Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

卡培他滨 拉帕蒂尼 医学 内科学 转移性乳腺癌 曲妥珠单抗 临床终点 肿瘤科 耐受性 乳腺癌 中期分析 癌症 随机对照试验 外科 不利影响 结直肠癌
作者
Binghe Xu,Min Yan,Fei Ma,Xichun Hu,J. Feng,Quchang Ouyang,Zhongsheng Tong,Huiping Li,Qingyuan Zhang,Tao Sun,Xian Wang,Yongmei Yin,Ying Cheng,Wěi Li,Xiaoyu Zhu,Chunxia Chen,Jianjun Zou
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (15_suppl): 1003-1003 被引量:28
标识
DOI:10.1200/jco.2020.38.15_suppl.1003
摘要

1003 Background: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine showed clinically meaningful benefits and acceptable tolerability in patients (pts) with HER2+ metastatic breast cancer (MBC) in phase 1 and 2 studies. Methods: This open-label, multicenter, randomized phase 3 study enrolled HER2+ MBC pts after trastuzumab and taxanes, and/or anthracyclines. Up to two prior lines of chemotherapy (chemo) for metastatic disease were allowed. Pts were randomly assigned (1:1) to receive pyrotinib 400 mg or lapatinib 1250 mg qd continuously plus capecitabine 1000 mg/m 2 bid on days 1–14 of 21-day cycles. The primary endpoint was progression-free survival (PFS) per blinded independent central review. Results: From Jul 2017 to Oct 2018, 267 pts were randomized to the pyrotinib (n=134) or lapatinib (n=133) arm. One pt in the lapatinib arm did not receive study treatment and was excluded from analyses. 42.5% and 34.8% of pts in the pyrotinib and lapatinib arm had no prior chemo for metastatic disease, 41.8% and 49.2% had one prior line, and 15.7% and 15.9% had two lines. At the planned interim analysis, the median PFS was 12.5 months (95% CI 9.7–not reached) with pyrotinib plus capecitabine vs 6.8 months (95% CI 5.4–8.1) with lapatinib plus capecitabine (HR 0.39 [95% CI 0.27–0.56]; P<0.0001), which met the criterion for statistical significance (≤0.0066). Among trastuzumab-resistant pts, prolonged PFS with pyrotinib plus capecitabine was also observed (12.5 months [95% CI 6.9 to not reached] vs 6.9 months [95% CI 5.4 to not reached]; HR 0.60 [95% CI 0.29 to 1.21]). Benefits in objective response rate, clinical benefit rate, and duration of response with pyrotinib plus capecitabine were also indicated (Table). The most common grade ≥3 adverse events were diarrhea (30.6% vs 8.3% in the pyrotinib vs lapatinib arm) and hand-foot syndrome (16.4% vs 15.2%). Conclusions: In pts with HER2+ MBC after trastuzumab and chemo, pyrotinib plus capecitabine achieved a significant better PFS than lapatinib plus capecitabine, with manageable toxicity, verifying the phase 2 findings. Clinical trial information: NCT03080805 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
余舟唱晚关注了科研通微信公众号
刚刚
MrLiu完成签到,获得积分10
1秒前
日晖下浅浅的微笑完成签到,获得积分20
1秒前
luermei完成签到,获得积分10
1秒前
1秒前
orixero的应助被川里九樱采纳,获得10
1秒前
小拉卡咪发布了新的文献求助10
1秒前
情怀的应助被yu采纳,获得10
2秒前
2秒前
多多发布了新的文献求助10
3秒前
无花果的应助被菲菲采纳,获得10
3秒前
3秒前
苹果新竹完成签到,获得积分10
4秒前
4秒前
Akim的应助被qqqqqqqqqq采纳,获得50
4秒前
KayneJia完成签到,获得积分10
4秒前
FashionBoy的应助被大橙子采纳,获得10
5秒前
丘比特的应助被犹豫忆南采纳,获得10
5秒前
Jasper的应助被平平淡淡采纳,获得10
5秒前
5秒前
经十路以东的应助被皮卡布采纳,获得10
7秒前
Huang完成签到 ,获得积分10
7秒前
科研通AI6.2的应助被皮卡布采纳,获得10
8秒前
8秒前
8秒前
8秒前
9秒前
挽风发布了新的文献求助10
9秒前
1733发布了新的文献求助20
10秒前
Orange的应助被小沈采纳,获得10
10秒前
gfydsl发布了新的文献求助10
11秒前
酷波er的应助被雾散采纳,获得10
12秒前
12秒前
13秒前
13秒前
经十路以东的应助被李佳佳采纳,获得10
13秒前
13秒前
14秒前
伍寒烟发布了新的文献求助10
14秒前
克里斯蒂娜完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194107
求助须知:如何正确求助?哪些是违规求助? 9580062
关于积分的说明 21869017
捐赠科研通 7793713
什么是DOI,文献DOI怎么找? 3437523
关于科研通互助平台的介绍 2560962
邀请新用户注册赠送积分活动 2484264